PolTREG Treg cell therapy for patients with type-1 diabetes - GlobeNewswire
PTG-007 Treg cell therapy showed clinical remission in type-1 diabetes patients for up to 12 years, with some remaining insulin-independent for 24 months. The therapy is set to enter a pivotal study, with data presented at the INNODIA EASD conference.
Highlighted Terms
Related News
PTG-007 cell therapy led to clinical remission in T1D patients for up to 12 years, with some insulin-independent for 24 months. PTG-007 is set for a pivotal study, with data presented at INNODIA EASD conference.
PolTREG's PTG-007 cell therapy showed clinical remission for type 1 diabetes up to 12 years post-treatment, prompting plans for a Phase II/III trial and partnership funding.
PTG-007 Treg cell therapy showed clinical remission in T1D patients for up to 12 years, with some insulin-independent for 24 months. PTG-007 is set to enter a pivotal study, with data presented at INNODIA EASD conference.
PTG-007 Treg cell therapy showed clinical remission in type-1 diabetes patients for up to 12 years, with some remaining insulin-independent for 24 months. The therapy is set to enter a pivotal study, with data presented at the INNODIA EASD conference.